In the version of this article initially published, the fourth sentence in the Online Methods section "RNA extraction and library preparation, " that read in part "procedure that combines a random priming step with a shearing step 8,9,28 and results in fragments of ~700 bp in size, " should have read, "procedure that combines fragmentation of mRNA to a peak size of ~750 nucleotides by heating 6 followed by random-primed reverse transcription 8 . " The error has been corrected in the HTML and PDF versions of the article. In the version of this article initially published, in Table 1 , the Emergent BioSolutions' anthrax countermeasures in development listed AV-7909 as being in phase 2 under a $447.6 million BARDA contract; AV-7909 is in phase 1 and the BARDA contract is for $29.7 million. AIGIV is in phase 1/3, not phase 1/2. Finally, a third product was omitted; anthrax monoclonal is in preclinical testing under a $24 million BARDA contract. The $447.6 million BARDA contract was for procurement and product enhancements on BioThrax. Also, on p.188, column 2, line 7, the vaccine requires five injections, not six as originally stated. The error has been corrected in the HTML and PDF versions of the article. In the version of this article initially published, references 4 and 7 were inadvertently interchanged. The error has been corrected in the HTML and PDF versions of the article.
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Erratum: Single base-resolution methylome of the silkworm reveals a sparse epigenomic map
